Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer

被引：2

作者：

Piotrowska, Zofia ^{[1
]}

Sequist, Lecia V. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 03期

关键词：

ACQUIRED-RESISTANCE; INHIBITOR; HETEROGENEITY; MECHANISMS; AZD9291; MUTATIONS; THERAPY; GENE; BRAF;

D O I：

10.1016/j.jtho.2017.01.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：419 / 421

页数：3

共 50 条

[41] MERTK activation drives osimertinib resistance in EGFR-mutant non small cell lung cancer
Yan, Dan
Huelse, Justus M.
Kireev, Dmitri
Tan, Zikang
Chen, Luxiao
Goyal, Subir
Wang, Xiaodong
Frye, Stephen, V
Behera, Madhusmita
Schneider, Frank
Ramalingam, Suresh S.
Owonikoko, Taofeek
Earp, H. Shelton
DeRyckere, Deborah
Graham, Douglas K.
JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (15):
[42] Switch to MET oncogene dependence as a novel mechanism of drug resistance in EGFR-mutant lung cancer
Eser, Pinar O.
Paranal, Raymond M.
Poitras, Michael J.
Xu, Man
Wang, Stephen
Ogino, Atsuko
Choi, Jihyun
Missios, Pavlos
Haikala, Heidi M.
Son, Jieun
Lin, Mika
Yanagita, Masahiko
Gokhale, Prafulla C.
Daley, George Q.
Janne, Pasi A.
CANCER RESEARCH, 2019, 79 (13)
[43] Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
Nakagawa, Takayuki
Takeuchi, Shinji
Yamada, Tadaaki
Nanjo, Shigeki
Ishikawa, Daisuke
Sano, Takako
Kita, Kenji
Nakamura, Takahiro
Matsumoto, Kunio
Suda, Kenichi
Mitsudomi, Tetsuya
Sekido, Yoshitaka
Uenaka, Toshimitsu
Yano, Seiji
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (10) : 2149 - 2157
[44] Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
Cai, Xueting
Miao, Jing
Sun, Rongwei
Wang, Sainan
Molina-Vila, Miguel Angel
Chaib, Imane
Rosell, Rafael
Cao, Peng
PHARMACOLOGICAL RESEARCH, 2021, 170
[45] A Case of Small Cell Lung Cancer Transformation from EGFR-Mutant Lung Adenocarcinoma with Primary Resistance to Gefitinib
Chu, Xiao
Li, Yuan
Zhu, Zhengfei
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : E211 - E214
[46] Dramatic Response to Afatinib in EGFR-Mutant Lung Adenocarcinomas After Resistance to First-Generation EGFR Inhibitors: A Brief Report
Li, W.
Yang, J.
Chen, H.
Li, A.
Lin, J.
Tu, H.
Su, J.
Zhang, X.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2221 - S2221
[47] miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance
Ricciuti, Biagio
Mecca, Carmen
Cenci, Matteo
Leonardi, Giulia Costanza
Perrone, Lorenzo
Mencaroni, Clelia
Crino, Lucio
Grignani, Francesco
Baglivo, Sara
Chiari, Rita
Sidoni, Angelo
Paglialunga, Luca
Curra, Maria Francesca
Murano, Emanuele
Minotti, Vincenzo
Metro, Giulio
ECANCERMEDICALSCIENCE, 2015, 9
[48] Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR-mutant lung cancer
Momcilovic, Milica
Bailey, Sean T.
Lee, Jason T.
Magyar, Clara
Braas, Daniel
Graeber, Thomas
Parlati, Francesco
Demo, Susan
Krysan, Konstyantyn
Walser, Tonya C.
Dubinett, Steven M.
Sadeghi, Saman
Christofk, Heather R.
Shackelford, David B.
CLINICAL CANCER RESEARCH, 2018, 24 (17)
[49] Optimizing the Sequence of Anti-EGFR-Targeted Therapy in EGFR-Mutant Lung Cancer
Meador, Catherine B.
Jin, Hailing
de Stanchina, Elisa
Nebhan, Caroline A.
Pirazzoli, Valentina
Wang, Lu
Lu, Pengcheng
Vuong, Huy
Hutchinson, Katherine E.
Jia, Peilin
Chen, Xi
Eisenberg, Rosana
Ladanyi, Marc
Politi, Katerina
Zhao, Zhongming
Lovly, Christine M.
Cross, Darren A. E.
Pao, William
MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 542 - 552
[50] ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?
Piotrowska, Zofia
Gainor, Justin F.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) : 2241 - +

← 1 2 3 4 5 →